Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New dialysis fluid may prevent dangerous blood pressure crashes in ICU

NCT ID NCT05936710

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two types of dialysis fluid—citrate-based versus acetate-based—to see which one causes fewer blood pressure drops during dialysis in intensive care unit (ICU) patients. About 48 adults with acute kidney failure who are at risk for low blood pressure will take part. The goal is to find a safer way to perform dialysis in critically ill patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 48 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2023

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient ≥ 18 years old * Patient hospitalized in an intensive care unit * Patient with acute renal failure defined by a KDIGO stage ≥ 1 and suspected non-obstructive * Patient at risk of per dialytic hypotension (capillary refill time ≥ 3 seconds and/or cardiovascular SOFA ≥ 1 and/or lactatemia \> 2mmol/L) * Indication for Extra Renal Replacement Therapy with IHD. Exclusion Criteria: * Pregnant or breastfeeding woman * Known chronic renal insufficiency of any stage * Cardio-renal and hepato renal syndrome * Unstable hemodynamic state: refractory shock * Patient included in another interventional study likely to modify the hemodynamic state * Patient deprived of liberty * Patient under guardianship or curatorship * Patient not affiliated to a social security system

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute renal failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHRU Nancy

    RECRUITING

    Nancy, France

  • CHU

    RECRUITING

    Caen, France

  • CHU de ROUEN

    NOT_YET_RECRUITING

    Rouen, 59507, France

  • Centre Hospitalier Béthune

    RECRUITING

    Béthune, 62408, France

  • Centre Hospitalier Universitaire de Dijon

    RECRUITING

    Dijon, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.